| Issuer | % of Class | Filed |
|---|---|---|
|
Aligos Therapeutics, Inc.
13D
ALGS · 01626L204
|
5.6% |
6/24/2026
Event 6/16/2026
|
|
Aligos Therapeutics, Inc.
13G
ALGS · 01626L204
|
5.1% |
5/15/2026
Event 3/31/2026
|
|
Aligos Therapeutics, Inc.
13D/A
Amendment 1
ALGS · 01626L204
|
3.2% |
3/12/2025
Event 3/10/2025
|
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.